{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:27:25Z","timestamp":1781796445433,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003327","name":"Cooperative Research Centres, Australian Government Department of Industry","doi-asserted-by":"publisher","award":["CRCPFIVE000141"],"award-info":[{"award-number":["CRCPFIVE000141"]}],"id":[{"id":"10.13039\/501100003327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003327","name":"Cooperative Research Centres, Australian Government Department of Industry","doi-asserted-by":"publisher","award":["CRCPFIVE000141"],"award-info":[{"award-number":["CRCPFIVE000141"]}],"id":[{"id":"10.13039\/501100003327","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000924","name":"Multiple Sclerosis Research Australia","doi-asserted-by":"publisher","award":["18-0461"],"award-info":[{"award-number":["18-0461"]}],"id":[{"id":"10.13039\/501100000924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Modern management of MS targets No Evidence of Disease Activity (NEDA): no clinical relapses, no magnetic resonance imaging (MRI) disease activity and no disability worsening. While MRI is the principal tool available to neurologists for monitoring clinically silent MS disease activity and, where appropriate, escalating treatment, standard radiology reports are qualitative and may be insensitive to the development of new or enlarging lesions. Existing quantitative neuroimaging tools lack adequate clinical validation. In 397 multi-center MRI scan pairs acquired in routine practice, we demonstrate superior case-level sensitivity of a clinically integrated AI-based tool over standard radiology reports (93.3% vs 58.3%), relative to a consensus ground truth, with minimal loss of specificity. We also demonstrate equivalence of the AI-tool with a core clinical trial imaging lab for lesion activity and quantitative brain volumetric measures, including percentage brain volume loss (PBVC), an accepted biomarker of neurodegeneration in MS (mean PBVC \u22120.32% vs \u22120.36%, respectively), whereas even severe atrophy (&gt;0.8% loss) was not appreciated in radiology reports. Finally, the AI-tool additionally embeds a clinically meaningful, experiential comparator that returns a relevant MS patient centile for lesion burden, revealing, in our cohort, inconsistencies in qualitative descriptors used in radiology reports. AI-based image quantitation enhances the accuracy of, and value-adds to, qualitative radiology reporting. Scaled deployment of these tools will open a path to precision management for patients with MS.<\/jats:p>","DOI":"10.1038\/s41746-023-00940-6","type":"journal-article","created":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T03:03:17Z","timestamp":1697684597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-8864","authenticated-orcid":false,"given":"Michael","family":"Barnett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Beadnall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-5738","authenticated-orcid":false,"given":"Antje","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brunacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7737-5834","authenticated-orcid":false,"given":"J. William L.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Cabezas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilak","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tej","family":"Dugal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Guilfoyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Klistorner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kain","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-4363","authenticated-orcid":false,"given":"Zihao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-0529","authenticated-orcid":false,"given":"Kayla","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Wiendl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zivadinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7135-7662","authenticated-orcid":false,"given":"Chenyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,19]]},"reference":[{"key":"940_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton, C. et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult. Scler. 26, 1816\u20131821 (2020).","journal-title":"Mult. Scler."},{"key":"940_CR2","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ana.25463","volume":"85","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Silent progression in disease activity-free relapsing multiple sclerosis. Ann. Neurol. 85, 653\u2013666 (2019).","journal-title":"Ann. Neurol."},{"key":"940_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos, L. et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 77, 1132\u20131140 (2020).","journal-title":"JAMA Neurol."},{"key":"940_CR4","doi-asserted-by":"publisher","first-page":"104899","DOI":"10.1016\/j.msard.2023.104899","volume":"78","author":"D Sharrad","year":"2023","unstructured":"Sharrad, D., Chugh, P., Slee, M. & Bacchi, S. Defining progression independent of relapse activity (PIRA) in adult patients with relapsing multiple sclerosis: a systematic review. Mult. Scler. Relat. Disord. 78, 104899 (2023).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"940_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/WCO.0000000000001067","volume":"35","author":"M Barnett","year":"2022","unstructured":"Barnett, M., Barnett, Y. & Reddel, S. MRI and laboratory monitoring of disease-modifying therapy efficacy and risks. Curr. Opin. Neurol. 35, 278\u2013285 (2022).","journal-title":"Curr. Opin. Neurol."},{"key":"940_CR6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol, A. et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 79, 682\u2013692 (2022).","journal-title":"JAMA Neurol."},{"key":"940_CR7","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1212\/WNL.0b013e3181e24136","volume":"74","author":"N De Stefano","year":"2010","unstructured":"De Stefano, N. et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74, 1868\u20131876 (2010).","journal-title":"Neurology"},{"key":"940_CR8","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.msard.2017.12.016","volume":"20","author":"G Lu","year":"2018","unstructured":"Lu, G. et al. The evolution of \u201cNo Evidence of Disease Activity\u201d in multiple sclerosis. Mult. Scler. Relat. Disord. 20, 231\u2013238 (2018).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"940_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1176\/appi.neuropsych.13040088","volume":"27","author":"DE Ross","year":"2015","unstructured":"Ross, D. E., Ochs, A. L., DeSmit, M. E., Seabaugh, J. M. & Havranek, M. D., Alzheimer\u2019s Disease Neuroimaging I. Man versus machine Part 2: comparison of radiologists\u2019 interpretations and NeuroQuant measures of brain asymmetry and progressive atrophy in patients with traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 27, 147\u2013152 (2015).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"940_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1176\/appi.neuropsych.11120377","volume":"25","author":"DE Ross","year":"2013","unstructured":"Ross, D. E., Ochs, A. L., Seabaugh, J. M. & Shrader, C. R., Alzheimer\u2019s Disease Neuroimaging I. Man versus machine: comparison of radiologists\u2019 interpretations and NeuroQuant(R) volumetric analyses of brain MRIs in patients with traumatic brain injury. J. Neuropsychiatry Clin. Neurosci. 25, 32\u201339 (2013).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"940_CR11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/jon.12650","volume":"29","author":"MG Dwyer","year":"2019","unstructured":"Dwyer, M. G. et al. Salient central lesion volume: a standardized novel fully automated proxy for brain FLAIR lesion volume in multiple sclerosis. J. Neuroimaging 29, 615\u2013623 (2019).","journal-title":"J. Neuroimaging"},{"key":"940_CR12","doi-asserted-by":"publisher","first-page":"102312","DOI":"10.1016\/j.media.2021.102312","volume":"76","author":"RA Kamraoui","year":"2022","unstructured":"Kamraoui, R. A. et al. DeepLesionBrain: towards a broader deep-learning generalization for multiple sclerosis lesion segmentation. Med. Image Anal. 76, 102312 (2022).","journal-title":"Med. Image Anal."},{"key":"940_CR13","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1109\/JBHI.2022.3151741","volume":"26","author":"Y Ma","year":"2022","unstructured":"Ma, Y. et al. Multiple sclerosis lesion analysis in brain magnetic resonance images: techniques and clinical applications. IEEE J. Biomed. Health Inf. 26, 2680\u20132692 (2022).","journal-title":"IEEE J. Biomed. Health Inf."},{"key":"940_CR14","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1177\/13524585211061339","volume":"28","author":"A Rovira","year":"2022","unstructured":"Rovira, A. et al. Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. Mult. Scler. 28, 1209\u20131218 (2022).","journal-title":"Mult. Scler."},{"key":"940_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00234-022-03074-w","volume":"65","author":"Z Mendelsohn","year":"2023","unstructured":"Mendelsohn, Z. et al. Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence. Neuroradiology 65, 5\u201324 (2023).","journal-title":"Neuroradiology"},{"key":"940_CR16","doi-asserted-by":"crossref","unstructured":"\u00c7i\u00e7ek, \u00d6, Abdulkadir, A., Lienkamp, S. S., Brox, T., Ronneberger, O. 3D U-Net: learning dense volumetric segmentation from sparse annotation. In Proc. International Conference on Medical Image Computing and Computer-Assisted Intervention: 2016.","DOI":"10.1007\/978-3-319-46723-8_49"},{"key":"940_CR17","unstructured":"Cabezas, ML, Y., Kyle, K., Ly, L., Wang, C., Barnett, M. Estimating lesion activity through feature similarity: a dual path Unet approach for the MSSEG2 MICCAI challenge. In Proc. 2nd MICCAI Challenge on Multiple Sclerosis New Lesions Segmentation Challenge Using a Data Management and Processing Infrastructure. MICCAI-MSSEG-2. Edited by Commowick FC, F.; Cotton, F.; Dojat, M. 107\u2013110 (2021)."},{"key":"940_CR18","doi-asserted-by":"publisher","unstructured":"Tang, Z. et al. LG-Net: lesion gate network for multiple sclerosis lesion inpainting. In: de Bruijne, M. et al. Medical Image Computing and Computer Assisted Intervention\u2014MICCAI 2021. Lecture Notes in Computer Science, vol 12907. https:\/\/doi.org\/10.1007\/978-3-030-87234-2_62 (Springer, Cham, 2021).","DOI":"10.1007\/978-3-030-87234-2_62"},{"key":"940_CR19","doi-asserted-by":"publisher","first-page":"1196087","DOI":"10.3389\/fnins.2023.1196087","volume":"17","author":"G Zhan","year":"2023","unstructured":"Zhan, G. et al. Learning from pseudo-labels: deep networks improve consistency in longitudinal brain volume estimation. Front. Neurosci. 17, 1196087 (2023).","journal-title":"Front. Neurosci."},{"key":"940_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.nicl.2013.10.015","volume":"4","author":"K Nakamura","year":"2014","unstructured":"Nakamura, K. et al. Jacobian integration method increases the statistical power to measure grey matter atrophy in multiple sclerosis. Neuroimage Clin. 4, 10\u201317 (2014).","journal-title":"Neuroimage Clin."},{"key":"940_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1212\/WNL.0b013e31827b910b","volume":"80","author":"A Minagar","year":"2013","unstructured":"Minagar, A. et al. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 80, 210\u2013219 (2013).","journal-title":"Neurology"},{"key":"940_CR22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp-2016-314597.33","volume":"87","author":"N De Stefano","year":"2016","unstructured":"De Stefano, N. et al. Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 87, 93\u201399 (2016).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"940_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/NEJM199801293380502","volume":"338","author":"BD Trapp","year":"1998","unstructured":"Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278\u2013285 (1998).","journal-title":"N. Engl. J. Med."},{"key":"940_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.1255","volume":"50","author":"JW Prineas","year":"2001","unstructured":"Prineas, J. W. et al. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 50, 646\u2013657 (2001).","journal-title":"Ann. Neurol."},{"key":"940_CR25","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1177\/1352458520974357","volume":"27","author":"S Klistorner","year":"2021","unstructured":"Klistorner, S. et al. Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients. Mult. Scler. 27, 1533\u20131542 (2021).","journal-title":"Mult. Scler."},{"key":"940_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kramer","year":"2023","unstructured":"Kramer, J., Bar-Or, A., Turner, T. J. & Wiendl, H. Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat. Rev. Neurol. 19, 289\u2013304 (2023).","journal-title":"Nat. Rev. Neurol."},{"key":"940_CR27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.neurad.2020.01.083","volume":"47","author":"JC Brisset","year":"2020","unstructured":"Brisset, J. C. et al. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: special consideration for gadolinium deposition and frequent acquisitions. J. Neuroradiol. 47, 250\u2013258 (2020).","journal-title":"J. Neuroradiol."},{"key":"940_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes, M. P. et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 20, 653\u2013670 (2021).","journal-title":"Lancet Neurol."},{"key":"940_CR29","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s00415-006-0503-6","volume":"254","author":"M Calabrese","year":"2007","unstructured":"Calabrese, M. et al. Cortical atrophy is relevant in multiple sclerosis at clinical onset. J. Neurol. 254, 1212\u20131220 (2007).","journal-title":"J. Neurol."},{"key":"940_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ncl.2017.08.013","volume":"36","author":"A Giorgio","year":"2018","unstructured":"Giorgio, A. & De Stefano, N. Effective utilization of MRI in the diagnosis and management of multiple sclerosis. Neurol. Clin. 36, 27\u201334 (2018).","journal-title":"Neurol. Clin."},{"key":"940_CR31","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1136\/jnnp-2012-304094","volume":"84","author":"V Popescu","year":"2013","unstructured":"Popescu, V. et al. Brain atrophy and lesion load predict long term disability in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 84, 1082\u20131091 (2013).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"940_CR32","doi-asserted-by":"publisher","first-page":"175628641882346","DOI":"10.1177\/1756286418823462","volume":"12","author":"HN Beadnall","year":"2019","unstructured":"Beadnall, H. N. et al. Comparing longitudinal brain atrophy measurement techniques in a real-world multiple sclerosis clinical practice cohort: towards clinical integration? Ther. Adv. Neurol. Disord. 12, 1756286418823462 (2019).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"940_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/nimg.2002.1040","volume":"17","author":"SM Smith","year":"2002","unstructured":"Smith, S. M. et al. Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage 17, 479\u2013489 (2002).","journal-title":"Neuroimage"},{"key":"940_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40263-017-0415-2","volume":"31","author":"N De Stefano","year":"2017","unstructured":"De Stefano, N., Silva, D. G. & Barnett, M. H. Effect of Fingolimod on brain volume loss in patients with multiple sclerosis. CNS Drugs 31, 289\u2013305 (2017).","journal-title":"CNS Drugs"},{"key":"940_CR35","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","volume":"89","author":"AJ Coles","year":"2017","unstructured":"Coles, A. J. et al. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89, 1117\u20131126 (2017).","journal-title":"Neurology"},{"key":"940_CR36","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/13524585231162586","volume":"29","author":"S Kolind","year":"2023","unstructured":"Kolind, S. et al. Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging. Mult. Scler. 29, 741\u2013747 (2023).","journal-title":"Mult. Scler."},{"key":"940_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1177\/1352458506070775","volume":"12","author":"H Butzkueven","year":"2006","unstructured":"Butzkueven, H. et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult. Scler. 12, 769\u2013774 (2006).","journal-title":"Mult. Scler."},{"key":"940_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.neuroimage.2011.02.046","volume":"56","author":"B Patenaude","year":"2011","unstructured":"Patenaude, B., Smith, S. M., Kennedy, D. N. & Jenkinson, M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 56, 907\u2013922 (2011).","journal-title":"Neuroimage"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00940-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00940-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T12:30:05Z","timestamp":1700310605000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-023-00940-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,19]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1038\/s41746-023-00940-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.14.23293959","asserted-by":"object"}]},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,19]]},"assertion":[{"value":"20 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial\/non-financial competing interests: D.W., K.K., L.L., A.S., Z.T., G.Z. and C.W. are employees of Sydney Neuroimaging Analysis Centre (SNAC); M.B. is a consulting neurologist and director for research at SNAC; T.D. and Y.B. are consulting radiologists at SNAC. C.W. and Y.B. personally hold equity ownership in SNAC, the entity that manufactures iQ-Solutions<sup>TM<\/sup>","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"196"}}